Genzyme, Arecor Enter Protein Pact

Genzyme Corp. and Arecor Ltd. have entered an extensive collaboration agreement to develop advanced formulations for protein therapeutics. The two companies will work together to develop stable, high strength formulations of labile biomolecules.

Dr. Robert Mattaliano, group vice president of Therapeutic Protein R&D commented, “The Arecor technology has a demonstrated potential to significantly improve the stability of complex biologicals by using novel formulation design principles. Genzyme is pleased to establish this strategic partnership in support of our goal to provide stable and convenient dosage forms to patients and their caregivers.”

Tom Saylor, chief executive officer of Arecor said, “Formulation of the next generation of biologics represents unique challenges to developers. Arecor has developed a strong partnership with Genzyme and is privileged to work closely with one of the world leaders in biotechnology to help enable new protein-based therapeutics.”